{
    "clinical_study": {
        "@rank": "149801", 
        "acronym": "iNew Trend", 
        "arm_group": [
            {
                "arm_group_label": "iBGStar (Group A)", 
                "arm_group_type": "Experimental", 
                "description": "Self-Monitoring Blood Glucose will be managed with iBGStar and iBGStar Diabetes Manager Application (App) uploaded on iPhone for all duration of the study (6 months of experimental phase plus 6-months of observational phase). In the first 3 months, the patients in Group A will send their glycemic test values and notes by mail to the physician through Diabetes Manager App every 2 weeks. Afterwards until the visit V2 (six months), the patients in Group A will send their glycemic test values and notes by mail monthly. 9 reports in total."
            }, 
            {
                "arm_group_label": "Traditional Glucometer (Group B)", 
                "arm_group_type": "Active Comparator", 
                "description": "Self-Monitoring Blood Glucose will be managed with a traditional glucometer according to usual care for the first 6 months (experimental phase). In the 6 months post-trial follow-up (observational phase), Self-Monitoring Blood Glucose will be managed with iBGStar and iBGStar Diabetes Manager App."
            }
        ], 
        "brief_summary": {
            "textblock": "The purpose of this study is to demonstrate the superiority of iBGstar as a component of the\n      diabetes treatment vs. traditional blood glucose self-monitoring system for improving\n      glycemic control after 6 months in young patients with type 1 diabetes. The study is\n      intended also to demonstrate the superiority of iBGStar as a component of the diabetes\n      treatment vs. usual blood glucose self-monitoring system for improving the compliance to\n      self monitoring of blood glucose after 6 months."
        }, 
        "brief_title": "Comparative Study of a Smartphone-Linked Self-Monitoring System Versus a Traditional One for Improving Metabolic Control and Compliance to Self-Monitoring of Blood Glucose", 
        "completion_date": {
            "#text": "April 2014", 
            "@type": "Anticipated"
        }, 
        "condition": "Diabetes Mellitus", 
        "condition_browse": {
            "mesh_term": "Diabetes Mellitus"
        }, 
        "detailed_description": {
            "textblock": "The planned study duration will be 20 months (5 quarters) with screening/enrollment of 7\n      months, followed by 2-3 weeks of a qualification phase, a 6 month experimental phase, plus a\n      6 month follow-up in the post-trial observational phase."
        }, 
        "eligibility": {
            "criteria": {
                "textblock": "Inclusion Criteria:\n\n          -  Type 1 diabetes\n\n          -  Males and females\n\n          -  Age between 14-24 years\n\n          -  Any diabetes duration\n\n          -  Cared for by the diabetes center for at least 1 year\n\n          -  HbA1c \u2265 8%\n\n          -  Basal bolus treatment (any insulin)\n\n          -  Poor compliance with Self-Monitoring of Blood Glucose (less than 30% of the\n             recommended Blood Glucose measurements recorded in the glucose meter in the two\n             previous weeks, i.e. <16 Blood Glucose measurements in the last two weeks)\n\n          -  Written informed consent obtained from patient or legal representative (for minor)\n\n        Exclusion Criteria:\n\n          -  Treatment with other insulin regimen or Continuous Subcutaneous Insulin Infusion\n\n          -  Refusal or inability to give informed consent to participate in the study\n\n          -  Patients with short life expectancy\n\n          -  Patients with conditions/concomitant diseases making them non evaluable for the\n             primary efficacy endpoint according to physician's judgment\n\n          -  Requirement for concomitant treatment that could bias primary evaluation\n\n          -  Patients with high likelihood of being unavailable for 6 and/or 12 months visits\n\n          -  Subject is the investigator, sub-investigator, research assistant, pharmacist, study\n             coordinator, other study site staff or relative of study site staff thus considered\n             directly involved in the conduct of the study\n\n          -  Current addition/abuse of alcohol or drugs\n\n          -  Severe visual or dexterity impairment\n\n          -  Patients with any mental condition rendering them unable to understand the nature,\n             scope, and possible consequences of the study\n\n          -  Pregnant or breast-feeding women\n\n          -  Subjects unlikely or unable to comply with the Protocol requirements"
            }, 
            "gender": "Both", 
            "healthy_volunteers": "No", 
            "maximum_age": "24 Years", 
            "minimum_age": "14 Years"
        }, 
        "enrollment": {
            "#text": "178", 
            "@type": "Anticipated"
        }, 
        "firstreceived_date": "February 25, 2014", 
        "has_expanded_access": "No", 
        "id_info": {
            "nct_id": "NCT02073188", 
            "org_study_id": "IBGST_L_05971"
        }, 
        "intervention": [
            {
                "arm_group_label": "iBGStar (Group A)", 
                "intervention_name": "iBGStar", 
                "intervention_type": "Device"
            }, 
            {
                "arm_group_label": "Traditional Glucometer (Group B)", 
                "intervention_name": "Traditional Glucometer", 
                "intervention_type": "Device"
            }
        ], 
        "is_fda_regulated": "Yes", 
        "is_section_801": "Yes", 
        "lastchanged_date": "February 26, 2014", 
        "number_of_arms": "2", 
        "official_title": "Comparative Efficacy of iBGStar Glucose Meter vs. Traditional Glucose Monitoring in Improving Metabolic Control and Compliance Towards Self-Monitoring of Blood Glucose in Young Patients With Type 1 Diabetes", 
        "overall_official": {
            "affiliation": "Sanofi", 
            "last_name": "Clinical Sciences & Operations", 
            "role": "Study Director"
        }, 
        "overall_status": "Active, not recruiting", 
        "oversight_info": {
            "authority": "Italy: Ethics Committee", 
            "has_dmc": "No"
        }, 
        "phase": "Phase 3", 
        "primary_completion_date": {
            "#text": "April 2014", 
            "@type": "Anticipated"
        }, 
        "primary_outcome": [
            {
                "measure": "Change in HbA1c levels from baseline", 
                "safety_issue": "No", 
                "time_frame": "baseline to six months"
            }, 
            {
                "measure": "Proportion of participants performing at least 30% of the recommended Self-Monitoring Blood Glucose tests after 6 months from randomization", 
                "safety_issue": "No", 
                "time_frame": "at 6 months"
            }
        ], 
        "required_header": {
            "download_date": "ClinicalTrials.gov processed this data on June 04, 2014", 
            "link_text": "Link to the current ClinicalTrials.gov record.", 
            "url": "http://clinicaltrials.gov/show/NCT02073188"
        }, 
        "responsible_party": {
            "responsible_party_type": "Sponsor"
        }, 
        "secondary_outcome": [
            {
                "measure": "Percentage of participants with HbA1c \u22647.5%", 
                "safety_issue": "No", 
                "time_frame": "at 6 months and 12 months"
            }, 
            {
                "measure": "Average number of recommended Self-Monitoring Blood Glucose tests daily, weekly, and monthly", 
                "safety_issue": "No", 
                "time_frame": "at 6 months and 12 months"
            }, 
            {
                "measure": "Mean fasting plasma glucose (FPG) and postprandial glucose (PPG)", 
                "safety_issue": "No", 
                "time_frame": "at 6 months and 12 months"
            }, 
            {
                "measure": "Mean Glycemic Variability", 
                "safety_issue": "No", 
                "time_frame": "at 6 months and 12 months"
            }, 
            {
                "measure": "Average Insulin Dose", 
                "safety_issue": "No", 
                "time_frame": "at 6 months and 12 months"
            }, 
            {
                "measure": "Number of Daily Injections", 
                "safety_issue": "No", 
                "time_frame": "at 6 months and 12 months"
            }, 
            {
                "measure": "Number of Insulin Dose Adjustments", 
                "safety_issue": "No", 
                "time_frame": "at 6 months and 12 months"
            }, 
            {
                "measure": "Quality of life:  Audit of Diabetes Dependent Quality of Life (ADDQOL)  (young adults 18-24 years)", 
                "safety_issue": "No", 
                "time_frame": "at 6 months and 12 months"
            }, 
            {
                "measure": "Diabetes Quality of Life (DQOL-Y) (adolescents 14-17 years)", 
                "safety_issue": "No", 
                "time_frame": "at 6 months and 12 months"
            }, 
            {
                "measure": "Participants satisfaction with SMBG meter assessed by Visual Analog Scale (VAS)", 
                "safety_issue": "No", 
                "time_frame": "at 6 months and 12 months"
            }, 
            {
                "measure": "Number overall contacts between centers and participants", 
                "safety_issue": "No", 
                "time_frame": "up to 12 months"
            }, 
            {
                "measure": "Type of overall contacts between centers and participants", 
                "safety_issue": "No", 
                "time_frame": "up to 12 months"
            }
        ], 
        "source": "Sanofi", 
        "sponsors": {
            "lead_sponsor": {
                "agency": "Sanofi", 
                "agency_class": "Industry"
            }
        }, 
        "start_date": "June 2012", 
        "study_design": "Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label", 
        "study_type": "Interventional", 
        "verification_date": "February 2014"
    }
}